Summary
Becton, Dickinson and Company (BDX) announced a change to its Board of Directors with the election of Carrie L. Byington, M.D., effective October 21, 2021. Dr. Byington's appointment is noteworthy as she brings external expertise to the board and will contribute to key committees. Dr. Byington's addition strengthens the board's oversight capabilities, particularly within the Audit Committee and the Quality and Regulatory Committee. Her independence, as determined by NYSE rules and BD's own governance principles, ensures an objective perspective. Investors should note that her compensation for this role will be in line with existing non-management director compensation practices, with an initial grant of restricted stock units.
Key Highlights
- 1Carrie L. Byington, M.D. has been elected to the Becton Dickinson (BD) Board of Directors, effective October 21, 2021.
- 2Dr. Byington will serve as a member of both the Audit Committee and the Quality and Regulatory Committee.
- 3The Board of Directors has determined Dr. Byington to be independent under NYSE rules and BD's Corporate Governance Principles.
- 4Dr. Byington's appointment brings additional expertise to the board's oversight functions.
- 5Her compensation will follow the established structure for non-management directors.
- 6She will receive restricted stock units valued at $54,969 as a prorated grant.
Frequently Asked Questions
While this filing doesn't detail her full professional background, Dr. Byington is a medical doctor and has been elected to the Board of Directors. Her specific expertise is not detailed here, but her appointment suggests a strategic addition to the board's oversight and governance.
Serving on the Audit Committee indicates her involvement in financial oversight and internal controls. Her role in the Quality and Regulatory Committee suggests a focus on BD's product quality, safety, and compliance with regulatory standards, which are critical aspects for a medical technology company.
Dr. Byington will be compensated in line with other non-management members of BD's Board of Directors. This includes an initial grant of restricted stock units valued at $54,969, which is prorated based on her joining date until the 2022 Annual Meeting of Shareholders.
Yes, BD's Board of Directors has determined that Dr. Byington is independent under the rules of the New York Stock Exchange and BD's own Statement of Corporate Governance Principles.